Moderna and the U.S. biotech sector surged dramatically—what’s behind this? What’s the outlook for the market going forward?

This week, U.S. healthcare and biotech stocks surged dramatically—Moderna (MRNA) jumped 177% in a single day. The sharp rise was triggered by Moderna and Merck’s announcement of positive results from a Phase 3 clinical trial of their jointly developed personalized mRNA cancer vaccine. After reviewing available materials, here’s a summary of the vaccine: The vaccine is named intismeran autogene (also known as V940 or mRNA-4157) and targets high-risk melanoma—a deadly form of skin cancer. Even after surgical removal of the tumor, many patients face a high likelihood of recurrence or metastasis. Here’s how the vaccine works: First, doctors take a sample of the patient’s tumor to identify the unique genetic mutations driving that specific cancer. Moderna then uses those mutations to manufacture a fully personalized vaccine for that individual patient. The goal is to train the patient’s immune system to recognize and eliminate cancer cells.

Testing volume up +32%, yet collection rate plunges to 32%: What’s happening at the U.S. leader in genetic testing?

# Testing Volume Up +32%, Yet Collection Rate Plummets to 32%: What’s Happening at the U.S. Genetic Testing Leader? U.S. genetic testing leader GeneDx released its Q2 2026 earnings report after market close on August 3. The report showed that its exome-plus-whole-genome sequencing tests totaled 30,785 cases—a 32% year-on-year increase—yet its outpatient genomic collection rate fell from 43% in the same period last year to just 32%. More tests are being performed—but less money is being collected. ## First, the Financials Q2 revenue stood at $114 million, up approximately 11% year-on-year; exome-plus-genome business revenue reached $100 million, up roughly 17%. Adjusted net income was $400,000—turning positive one quarter ahead of schedule. Average price per test remained flat at $3,258; whole-genome sequencing cost per case is approximately double that of exome sequencing. The CFO attributed the declining collection rate to “intentional market-development investment—scale first, collections will follow.” However, he acknowledged that collection rates may continue to fluctuate. ## Short-Seller Report On February 5, 2025, U.S. short-seller Grizzly Research published a report alleging fraud at GeneDx, citing internal whistleblower testimony. Key allegations include: - “Code stacking”: Using billing codes that do not meet eligibility criteria to overbill Medicare/Medicaid—an estimated 25% of reported revenue is allegedly inflated via this practice. Such conduct has been prohibited since 2013. - Executive awareness: A former vice president testified that the scale of the alleged misconduct necessitated direct involvement by the CEO, CFO, and CTO. - Prior incidents: In 2022, a billing dispute with UnitedHealthcare led to a $30 million revenue reduction for that quarter; in March 2023, the two parties settled, with GeneDx paying $42 million.

BioNexus Gene Lab Corp Stock Analysis Highlights Strong Fundamentals

Jul 27, 2026

TradingKey analyzes BioNexus Gene Lab Corp, citing strong fundamentals and fair valuation within the Biotechnology sector. Despite recent market weakness, the company maintains significant growth potential and high institutional confidence.

TradingKey

2026-05-12

BioNexus Gene Lab Corp (BGLC)

2026-06-18

BioNexus Gene Lab Corp (BGLC) Earnings Forecast: Future EPS & Revenue Growth Estimates

2026-06-18

BioNexus Gene Lab Corp (BGLC) Institutional Confidence

2026-06-18

BioNexus Gene Lab Corp (BGLC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

2026-06-18

BioNexus Gene Lab Corp Announces 10-to-1 Merger Stock Split